Mizuho Maintains Buy on Selecta Biosciences, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear maintains a Buy rating on Selecta Biosciences (NASDAQ:SELB) but lowers the price target from $4 to $3.

August 18, 2023 | 11:40 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mizuho has maintained a Buy rating on Selecta Biosciences but lowered the price target from $4 to $3.
While Mizuho's maintained Buy rating indicates a positive outlook for Selecta Biosciences, the lowered price target could potentially indicate a less optimistic future performance. This could have a neutral impact on the stock's price in the short term as the positive and negative signals balance each other out.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100